Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Consensus Price Target from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $55.50.

TVRD has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 8th.

Tvardi Therapeutics Price Performance

Shares of TVRD stock opened at $3.17 on Friday. The business’s fifty day moving average price is $3.87 and its 200 day moving average price is $9.44. Tvardi Therapeutics has a 1-year low of $3.15 and a 1-year high of $43.65. The firm has a market capitalization of $29.74 million, a PE ratio of -0.33 and a beta of 0.14.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TVRD. Arax Advisory Partners boosted its stake in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $43,000. HRT Financial LP acquired a new stake in shares of Tvardi Therapeutics during the fourth quarter valued at $47,000. Finally, XTX Topco Ltd acquired a new stake in shares of Tvardi Therapeutics during the 4th quarter worth about $55,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.